Rivastigmine in Parkinson’s disease dementia

References

• Hirtz D, Thurman DJ, Gwinn-Hardy K et al. How common are the “common” neurologic disorders? Neurology68(5), 326–337 (2007).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Denaro J, Hemenegildo N et al. A population-based investigation of Parkinson’s disease with and without dementia. Relationship to age and gender. Arch. Neurol.49(5), 492–497 (1992).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch. Neurol.60, 387–392 (2003).
   PubMed Web of Science ®Google Scholar
• Marder K, Tang MX, Cote L et al. The frequency and associated risk factors for dementia in patients with Parkinson’s disease. Arch. Neurol.52, 695–701 (1995).
   PubMed Web of Science ®Google Scholar
• Hughes TA, Ross HF, Musa S et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology54(8), 1596–1602 (2000).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology56(6), 730–736 (2001).
   PubMed Web of Science ®Google Scholar
• Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov. Disord.19(9), 1043–1049 (2004).
   PubMed Web of Science ®Google Scholar
• Caparros-Lefebvre D, Pécheux N, Petit V et al. Which factors predict cognitive decline in Parkinson’s disease? J. Neurol. Neurosurg. Psychiatry58(1), 51–55 (1995).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Andersen K, Larsen JP et al. The rate of cognitive decline in Parkinson disease. Arch. Neurol.61(12), 1906–1911 (2004).
   PubMed Web of Science ®Google Scholar
• Lieberman A. Are dementia and depression in Parkinson’s disease related? J. Neurol. Sci.248, 138–142 (2006).
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE et al. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J. Am. Geriatr. Soc.52, 784–788 (2004).
   PubMed Web of Science ®Google Scholar
• Foltynie T, Brayne CE, Robbins TW et al. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain127, 550–560 (2004).
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Wagstaff AJ. Rivastigmine in Parkinson’s disease dementia: profile report. Drugs Aging24(3), 255–259 (2007).
   PubMed Web of Science ®Google Scholar
• Bohnen NI, Kaufer DI, Ivanco LS et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch. Neurol.60(12), 1745–1748 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor P. Anticholinesterase agents. In: Goodman’s and Gilman’s (9th Ed). The Pharmacological Basis of Therapeutics. Hardman JG, Limbird LE (Eds), McGraw-Hill, New York, USA, 161–175 (1996).
   Google Scholar
• Grutzendler J, Morris J. Cholinesterase inhibitors for Alzheimer’s disease. Drugs61, 41–52 (2001).
   PubMed Web of Science ®Google Scholar
• McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356, 2031–2036 (2000).
   PubMed Web of Science ®Google Scholar
• Burn DJ, McKeith I. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov. Disord.18(Suppl. 6), S72–S79 (2003).
   PubMed Web of Science ®Google Scholar
• McKeith I, Mosimann UO. Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat. Disord.10, S15–S18 (2004).
   PubMed Web of Science ®Google Scholar
• Giladi N, Shabtai H, Gurevich T et al. Rivastigmine (Exelon) for dementia in patients with Parkinson’s disease. Acta Neurol. Scand.108(5), 368–373 (2003).
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord.16(6), 1171–1195 (2001).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18 (10), 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s disease. Clin. Neuropharmacol.25(2), 107–110 (2002).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Albanese A et al. Rivastigmine for the dementia associated with Parkinson’s disease. N. Engl. J. Med.351, 2509–2518 (2004).
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A et al. Donepezil for dementia in Parkinson’s disease: a randomised, double blind, placebo controlled, crossover study. J. Neurol. Neurosurg. Psychiatry76(7), 903–904 (2005).
   PubMed Web of Science ®Google Scholar
• McKeith IG, Burn D. Spectrum of Parkinson’s disease, Parkinson’s dementia, and Lewy body dementia. In: Neurologic Clinics. DeKosky ST (Ed.), WB Sauders, PA, USA, 865–883 (2000).
   Google Scholar
• Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol.2, 229–237 (2003).
   PubMed Web of Science ®Google Scholar
• Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology67, 1605–1611 (2006).
   PubMed Web of Science ®Google Scholar
• Hegemann-Richard I, Papka M, Rubio A et al. Parkinson’s disease and dementia with Lewy bodies one disease or two? Mov. Disord.17, 1161–1165 (2002).
   PubMed Web of Science ®Google Scholar
• McKeith I, Dickson DW, Lowe J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology65 (12), 1863–1872 (2005).
   PubMed Web of Science ®Google Scholar
• Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov. Disord.22, 1689–1707 (2007).
   PubMed Web of Science ®Google Scholar
• Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging13, 391–411 (1998).
   PubMed Web of Science ®Google Scholar
• Miyasaki J M, Shannon K, Voon V et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology66(7), 996–1002 (2006).
   PubMed Web of Science ®Google Scholar
• Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry51, 745–752 (1988).
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov. Disord.21(4), 456–461 (2006).
   PubMed Web of Science ®Google Scholar
• Jann MW. Rivastigmine, a new generation cholinesterase inhibitor for the treatment of Alzheimer’s disease. Pharmacotherapy20, 1–12 (2000).
   PubMed Web of Science ®Google Scholar
• McGleenon BM, Dynan KB, Passmore AP. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br. J. Clin. Pharmacol.48(4), 471–480 (1999).
   PubMed Web of Science ®Google Scholar
• Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer’s disease. Drugs Aging13, 391–411 (1998).
   PubMed Web of Science ®Google Scholar
• Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology69(4 Suppl. 1), S10–S13 (2007).
   PubMed Web of Science ®Google Scholar
• Cummings J, Winblad B. A Rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev. Neurother.7, 1457–1463 (2007).
   PubMedGoogle Scholar
• Hossain M, Jhee SS, Shiovitz T et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer’s type. Clin. Pharmacokinet.41(3), 225–234 (2002).
   PubMed Web of Science ®Google Scholar
• Cutler NR, Polinsky RJ, Sramek JJ et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol. Scand.97(4), 244–250 (1998).
   PubMed Web of Science ®Google Scholar
• Schran HF, Habucky K, Mancione LC et al. The effects of renal and hepatic impairment on the disposition of acetylcholinesterase SDZ ENA 713 [abstract]. Pharm. Res.13, S-428 (1996).
   Google Scholar
• Mesulam MM, Guillozet A, Shaw P et al. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine. Neuroscience110(4), 627–639 (2002).
   PubMed Web of Science ®Google Scholar
• Mesulam MM. Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer’s disease. In: Cholinesterases and Cholinesterase Inhibitors. Giacobini E (Ed.), Martin Dunitz, London, 121–138 (2000).
   Google Scholar
• Greig NH, Utsuki T, Ingram DK et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent. Proc. Natl Acad. Sci. USA102, 17213–17218 (2005).
   PubMed Web of Science ®Google Scholar
• Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology60(11), 1852–1853 (2003).
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Volterrani D, Frosini D et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia. J. Neural. Transm.113, 1787–1790 (2006).
   PubMed Web of Science ®Google Scholar
• Kuhl DE, Koeppe RA, Snyder SE et al.In vivo butyrylcholinesterase activity is not increased in Alzheimer’s disease synapses. Ann. Neurol.59(1), 13–20 (2006).
   PubMed Web of Science ®Google Scholar
• Burn D, Emre M, McKeith I et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov. Disord.21, 1899–1907 (2006).
   PubMed Web of Science ®Google Scholar
• Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst. Rev. (1), CD004747 (2006).
   Google Scholar
• Burns A, O’Brien J, BAP Dementia consensus group et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for psychopharmacology. J. Psychopharmacol.20, 732–755 (2006).
   PubMed Web of Science ®Google Scholar
• Mercier F, Lefèvre G, Huang HL. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr. Med. Res.Opin.23, 3199–3204 (2007).
   PubMed Web of Science ®Google Scholar
• Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry22, 456–467 (2007).
   PubMed Web of Science ®Google Scholar
• Lefèvre G , Sedek G, Jhee SS et al. Pharmacokinetics and pharmacodynamics of novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer’s disease patients. Clin. Pharmacol. Ther.83, 106–114 (2008).
   PubMed Web of Science ®Google Scholar
• Horstink M, Tolosa E, Bonuccelli U et al. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson’s disease. Neurology60(11), 1852–1853 (2003).
   PubMed Web of Science ®Google Scholar
• Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am. J. Psychiatry157(1), 4–15 (2000).
   PubMed Web of Science ®Google Scholar